Please assess the completion status of the following clinical trial:

Trial Title: Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* anxiety (score above 11 at anxiety scale of HADs)~* To have a prescription for 0.5 mg risperidone/day~* To give the consent~* To have a social protection~* To be adult (18-50 years)~Exclusion Criteria:~* Psychiatric antecedents~* any treatment for mental disease (antidepressant, anxiolytics, etc.)~* Ongoing neurological pathologies~* Scheduled surgery~* addiction~* pregancy~* known intolerance to risperidone~* participation to another biomedical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Responder (Type: OTHER): The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
- Non responder (Type: OTHER): The 2 arms will be created according to the early response to risperidone (responder vs. non responder)

Based on this trial design, predict the completion outcome and termination type (if applicable).